and pharmaceutically acceptable excipients with low water content comprising anhydrous lactose, microcrystalline cellulose, magnesium stearate, and talc.

9. (Amended Three Times) The pharmaceutical composition according to claim 6 wherein the pharmaceutically acceptable excipients are between 100 and 400,000 parts by weight of anhydrous lactose, between 1000 and 10,000 parts by weight of microcrystalline cellulose, and between 10 and 500 parts by weight of magnesium stearate, expressed in parts by weight per 100 parts of 5-[[4-[3-Methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenyl-methyl]thiazolidine-2,4-dione, or of one of its pharmaceutically acceptable salts.

29. (Amended Once) The pharmaceutical composition according to claim 6 consisting of 5-[[4-[3-methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenylmethyl] thiazolidine-2,4-dione or a pharmaceutically acceptable salt thereof 9%

Microcrystalline cellulose	20%
Anhydrous lactose	66%
Magnesium Stearate	0.5%
Talc	4.5%

## **REMARKS**

The specification has been amended to correct an editorial error which has heretofore gone unnoticed. Specifically, the term 5-[[4-[3-methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenylmethyl] thiadiazolidine-2,4-dione has been replaced with 5-[[4-[3-methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenylmethyl] thiazolidine-2,4-dione. The recitation of 5-[[4-[3-methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenylmethyl] thiadiazolidine-2,4-dione is an obvious error. Specifically, the recitation of 5-[[4-[3-methyl-4-oxo-3,4-dihydro-2-